Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 37591-37600 Newer>

The Motley Fool August 3, 2009	Today's 5-Star Movers LCA-Vision... Rexam PLC... Aluminum Corp. of China Limited... etc.
The Motley Fool August 3, 2009 Todd Wenning	One Way to Protect Your Gains Don't get fooled again. Done correctly, a cashless collar can provide you with peace of mind on a profitable position
The Motley Fool August 3, 2009 Rick Aristotle Munarriz	4 Dates to Circle in August It'll be a telltale month -- if you know what to look for when anticipating reports from important market leaders.
The Motley Fool August 3, 2009 Rick Aristotle Munarriz	7 Reasons Not to Worry This Week Not every company will be posting lower earnings this week.
The Motley Fool August 3, 2009 Selena Maranjian	What If the Market Stays Down for a While? Certain investors should be grinning at the opportunity.
Financial Planning August 1, 2009 Ilana Polyak	Critical Care As Congress wrestles with healthcare reform proposals under consideration, Kris Jenner, manager of the T. Rowe Price Health Sciences fund, is faced with just as difficult a task: how to make prudent investments in healthcare that can weather the seismic changes in the offing.
The Motley Fool August 2, 2009 Ilan Moscovitz	The Next 3 Dividend Burnouts? Paying close attention to how your company funds its dividend will help you achieve the golden returns that dividends offer.
The Motley Fool August 1, 2009 Rick Aristotle Munarriz	The Fool's Look Ahead Clorox, Humana, Cedar Fair, Cisco, International Flavors & Fragrances, MBIA, and OYO Geospace will be reporting their latest results this week.
The Motley Fool August 1, 2009 Rick Aristotle Munarriz	A Fool Looks Back Search and sedans exchanged high fives down Wall Street this week. Cash for Clunkers, Microsoft-Yahoo deals, SiriusXM, and Sprint were among the hot topics.
Chemistry World July 31, 2009 Matt Wilkinson	Agilent swoops on Varian Agilent is buying rival analytical instrument maker Varian for $1.5 billion ( 900 million) - a move that will increase its market share in the bioanalysis arena and mark its entry into the nuclear magnetic resonance (NMR) market.
<Older 37591-37600 Newer> Return to current articles.